GlaxoSmithKline's pricing of AZT to be investigated
BY Advocate.com Editors
December 20 2002 1:00 AM ET
Officials from the California Public Employees Retirement System, responding to complaints from AIDS advocates who say that pharmaceutical giant GlaxoSmithKline charges consumers 32 times the cost of making the anti-HIV drug AZT, announced Wednesday that they are launching an investigation into the pricing of the drug. CalPERS, the second-largest pension fund in the country, holds an estimated $1 billion in Glaxo stock. CalPERS officials plan to look into how Glaxo's pricing policies impact people in California who need anti-HIV medications and whether the cost of the drug is prohibitory. "We're heartened that CalPERS is willing to ask [Glaxo] for hard numbers on the pricing for AZT," said AIDS Healthcare Foundation spokesperson Ged Kenslea. "If Glaxo fails to comply, we will urge CalPERS and other investors to divest."
- Newly Out Fox Contributor Isn't Very Concerned About Gay Rights
- Out NYC Owners Call Gays 'Cheap,' 'Entitled' In Disastrous Interview
- Could National Marriage Equality Mean the End of Gay Culture?
- 9 Celebs Who Learned the Hard Way the T-Word Is Over
- Op-ed: When Right vs. Left Becomes Right vs. Wrong
- The Films of the 26th Annual Honolulu Rainbow Film Festival